Precision Biosciences (DTIL) Other Non Operating Income (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Other Non Operating Income of -$9.4 million for Q1 2026, down 705.43% year-over-year from $1.5 million in Q1 2025, and down 238.37% quarter-over-quarter from $6.8 million in Q4 2025.
Precision Biosciences (DTIL) Other Non Operating Income (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Other Non Operating Income for 9 consecutive years, with -$9.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 705.43% year-over-year to -$9.4 million; the TTM figure through Mar 2026 stood at -$5.3 million (down 124.18% YoY), while the FY2025 annual figure was $5.5 million, down 83.38% from the prior year.
- Other Non Operating Income declined to -$9.4 million in Q1 2026 per DTIL's latest filing, from $6.8 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $12.8 million in Q1 2024 and bottomed at -$9.4 million in Q1 2026.
- Historically, Other Non Operating Income has averaged $1.2 million across 5 years, with a median of $96000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 6270.83% — and 2024, when it soared 8861.46%.
- Precision Biosciences' Other Non Operating Income stood at -$7.3 million in 2022, then jumped by 119.9% to $1.5 million in 2023, then jumped by 387.71% to $7.1 million in 2024, then slipped by 4.68% to $6.8 million in 2025, then plunged by 238.37% to -$9.4 million in 2026.
- Business Quant data shows DTIL's Other Non Operating Income at -$9.4 million in Q1 2026, $6.8 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.49 Mn |
| Mar 31, 2026 | -9.37 Mn |
| Dec 31, 2025 | 6.77 Mn |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 7.10 Mn |
| Sep 30, 2024 | 4.85 Mn |
| Jun 30, 2024 | 8.60 Mn |
| Mar 31, 2024 | 12.78 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 253,000.00 |
| Jun 30, 2023 | 96,000.00 |
| Mar 31, 2023 | -596,000.00 |
| Dec 31, 2022 | -7.32 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.48 Mn |
| Mar 31, 2022 | -833,000.00 |
| Dec 31, 2021 | 5.65 Mn |
| Sep 30, 2021 | 263,000.00 |